Zalutumumab in Head and Neck Cancer
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
Head and Neck Neoplasms
DRUG: Zalutumumab
Adverse Events, Number of participants reporting at least one adverse event., From study start (Day 0) until follow-up period (up to Day 77)
Overall Response (OR), Classification, Best Overall Response is defined as the best response from the start of treatment until disease progression (PD) /recurrence and was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST). As per RECIST, PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started, OR the appearance of one or more new lesions., 8 weeks
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.